Name: 글로벌 시장 동향
SKU: PH7312
Availability: InStock

보고서 요약(국문)

개요
전 세계 야토병 치료 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY억 달러에 이를 것으로 예상됩니다.
전 세계 야토병 치료 시장은 여러 요인의 영향으로 지난 수년간 상당한 성장과 변화를 겪어왔습니다. 그람 음성, 호기성, 다형성 간균인 프란시셀라 툴라렌시스(Francisella tularensis)는 급성 육아종성 발열성 감염성 인수공통전염병인 야토병을 유발합니다. F. tularensis는 가장 전염성이 강한 세균 중 하나입니다.
야토병 환자의 최대 20%에서 반점, 얼룩 또는 반점구진 형태로 시작되어 농포성으로 진행되는 발진이 나타납니다. 다형홍반과 결절홍반은 드물게 발생합니다.

특히 개발도상국을 중심으로 한 정부 투자와 연구는 독시사이클린이나 스트렙토마이신과 같은 신약의 활용을 촉진하고, 야토병 치료제 시장을 활성화시킬 것입니다.
시장 동향: 성장 동인 및 제약 요인
협력 증가와 신약 출시
선진국들은 높은 투자, 소득 수준 향상, 인프라 개발에 힘입어 의료 부문이 빠르게 발전하고 있습니다. 여러 국가에서 연구 활동 증가로 야토병 치료제에 대한 수요가 증가하고 있습니다. 다양한 국가 간의 협력, 인수, 라이선스 계약 및 기술 발전은 시장 성장을 견인하는 중요한 요인이 될 것입니다.
2022년 2월 17일, 국방과학기술연구소(DSTL) 연구진은 요로 감염 치료를 위해 개발된 항생제가 페스트와 멜리오이도시스를 포함한 광범위한 질병 치료에 효과적임을 입증했습니다. 이 연구는 산업계, 학계, 그리고 국방위협감축국(DTRA)과의 협력을 통해 이루어졌습니다. 메를리온 파마슈티컬스(MerLion Pharmaceuticals)에서 제조하는 항생제 피나플록사신은 요로 감염 치료에 사용되지만, 기존 약물과 비교했을 때 독특한 작용 기전으로 효능이 향상되었습니다. 쥐 감염 모델에서 피나플록사신은 흡입성 야토병과 페스트를 효과적으로 치료하는 것으로 나타났습니다.
또한, 세계적인 제약 회사인 히크마 파마슈티컬스(Hikma Pharmaceuticals PLC)는 2021년 6월 25일 미국 자회사인 히크마 파마슈티컬스 USA(Hikma Pharmaceuticals USA Inc.)를 통해 독시사이클린 주사제(USP, 100mg)를 미국 시장에 출시했습니다. 독시사이클린 주사제는 항생제 감수성 세균에 의한 감염 치료에 사용됩니다.
더 나아가, 야토병 치료를 위한 신약 및 치료법의 활용 증가, 야토병 발병 사례 증가, 여러 약물의 사용 증가, 그리고 혁신적인 제품 개발 연구 등이 야토병 치료 시장 성장을 견인할 주요 요인입니다.

약물 관련 부작용
10명 중 1명은 독시사이클린의 부작용을 자주 경험합니다. 두통, 메스꺼움(구토), 구토, 햇빛에 대한 민감성 등이 부작용의 예입니다. 심각한 부작용은 혈액 관련 문제를 나타낼 수 있으며, 원인을 알 수 없는 출혈이나 멍(코피 포함), 인후통, 발열, 피로감 또는 전반적인 몸살 등이 있습니다.
혈변이나 점액변, 이명, 복부 경련, 삼키기 어려움 또는 통증, 인후통, 위산 역류, 식욕 부진, 식사 중 악화되는 흉통 등이 나타날 수 있습니다.
세분화 분석
전 세계 야토병 치료 시장은 질병 유형, 약물, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.

궤양림프절형 툴라레미아 질환 유형 부문은 시장 점유율의 약 48%를 차지했습니다.
북반구 전역에 널리 분포하는 프란시셀라 툴라렌시스(Francisella tularensis) 박테리아에 의해 발생하는 툴라레미아는 드문 인수공통감염병입니다. 진드기나 사슴파리와 같은 절지동물 매개체의 물림이나 토끼 또는 작은 설치류와 같은 자연 발생 동물 숙주의 오염된 조직을 만지는 것을 통해 감염됩니다.
오염된 체액이나 에어로졸에 노출되면 전신성 "장티푸스" 질환, 구강인두 질환, 안구림프절 질환 또는 폐렴성 질환이 발생할 수 있습니다. 과거에는 정맥 주사용 아미노글리코시드가 표준 치료법이었지만, 최근 연구에 따르면 경증의 경우 시프로플록사신이나 테트라사이클린과 같은 경구용 항생제로도 성공적으로 치료할 수 있는 것으로 나타났습니다. 인구 증가와 진드기 매개체의 지리적 분포 확대로 인해 전 세계적으로 툴라레미아 발병률이 증가할 것으로 예상됩니다.

일리노이주 공중보건부에 따르면 미국에서는 매년 100~200건의 툴라레미아 발병 사례가 보고됩니다. 툴라레미아는 6가지 유형의 질병을 유발할 수 있지만, 최대 80%의 사례는 "궤양성 림프절형"(피부 궤양과 림프절 비대가 특징)이며 감염된 동물과의 접촉을 통해 감염됩니다.
지리적 시장 점유율
북미는 2022년 시장 점유율의 약 39%를 차지했습니다.
의료 분야에서 툴라레미아 치료에 대한 수요가 증가함에 따라 북미 제조업체들은 사업 확장의 기회를 얻고 있습니다. 북미에는 많은 생산자와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 산업 생산이 확대되어 툴라레미아 치료제에 대한 수요를 견인하고 있습니다.
의료비 지출 증가, 기술 발전, 다양한 툴라레미아 질병 유형에 대한 다양한 치료 제품 개발, 그리고 이 지역의 바이오 제약 또는 생명 공학 기업 설립 증가는 이 지역의 툴라레미아 치료제 시장 점유율 성장에 기여하고 있습니다. 이 분야 시장은 다양한 신규 치료법에 대한 인식이 높아짐에 따라 성장하고 있습니다. 앞서 언급한 요소들은 북미가 세계에서 지배적인 위치를 차지하고 있음을 보여줍니다.
북미는 미국을 중심으로 세계 야토병 치료 시장에서 핵심적인 역할을 계속하고 있습니다. 인프라 개발 및 투자를 장려하는 정부 정책과 첨단 기술 발전에 대한 집중은 미국에서 아미노글리코사이드와 같은 항생제에 대한 수요를 촉진했습니다. 미국은 여러 치료법 개발에 적극적으로 나서면서 이러한 약물에 대한 수요를 자극해 왔습니다.
COVID-19 영향 분석
2019년 말 발생한 COVID-19 팬데믹은 전 세계 산업, 특히 세계 야토병 치료 시장에 전례 없는 어려움을 초래했습니다. 각국이 봉쇄, 공급망 차질, 경제 활동 감소에 직면하면서 플루오로퀴놀론 또는 테트라사이클린을 주요 소비처로 하는 제약 부문은 큰 타격을 입었습니다. 2020년 초부터 시작된 팬데믹으로 인한 광범위한 봉쇄와 제한 조치는 전 세계 여러 정책에 영향을 미쳤습니다.

주요 의료 및 생명공학 산업은 코로나19 관리로 인해 생산이 중단되고 관심이 코로나19로 쏠리면서 툴라레미아 치료제 수요가 급감했습니다. 그러나 현재 여러 연구가 재개되었고 기업들은 제품 효능에 대한 임상 시험을 다시 시작했습니다. 전반적으로 팬데믹이 세계 툴라레미아 치료제 시장에 미치는 영향은 비교적 경미할 것으로 예상되며, 새로운 치료법에 대한 지속적인 수요와 연구로 인해 시장은 꾸준히 성장할 전망입니다.
주요 개발 사항
• 2023년 8월 14일, 메인 파마 인터내셔널(Mayne Pharma International Pty. Ltd.)의 도릭스 MPC 서방정 및 도릭스 서방정의 제네릭 대체 의약품으로 시판될 수 있도록 미국 식품의약국(FDA)이 서방형 독시사이클린 히클레이트 정제 USP 50mg, 60mg, 80mg, 100mg, 150mg 및 200mg에 대한 약식 신약 허가 신청(ANDA)을 승인했습니다.
• 2022년 1월 4일, 미국 식품의약국(FDA)은 알렘빅 파마슈티컬스(Alembic Pharmaceuticals Limited)의 서방형 독시사이클린 히클레이트 정제 USP 100mg, 150mg 또는 200mg에 대한 약식 신약 허가 신청(ANDA)을 최종 승인했습니다. 승인된 ANDA는 Mayne Pharma International Pty. Ltd.의 Doryx 정제 100mg, 150mg 또는 200mg과 치료적으로 유사합니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Pfizer Inc., Merck KGaA, Fujian Fukang Pharmaceutical Co., Ltd, Hikma Pharmaceuticals PLC, Cepham Life Sciences, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Midas Pharma GmbH, Camber Pharmaceuticals, Inc. 및 FUJIFILM Wako Pure Chemical Corporation이 있습니다.
보고서 구매 이유

• 질병 유형, 약물, 투여 경로, 유통 채널 및 지역별 글로벌 야토병 치료 시장 세분화를 시각화하고 주요 상업적 자산 및 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 상업적 기회를 식별합니다.

• 모든 세그먼트를 포함한 야토병 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트.

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성되어 있습니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 야토병 치료 시장 보고서는 약 69개의 표, 70개의 그림, 186페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global tularemia treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global tularemia treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Francisella tularensis, a gram-negative, aerobic, pleomorphic bacillus, causes tularemia, an acute, granulomatous, febrile, infectious zoonosis. One of the most contagious bacterial species is F. tularensis.
Up to 20% of tularemia patients experience a rash that might start as macular, blotchy, or maculopapular before developing into pustular in nature. Erythema multiforme and erythema nodosum are uncommon.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced products for novel treatments such as doxycycline or streptomycin for glandular tularemia and boost the global tularemia treatment market.
Market Dynamics: Drivers & Restraints
Increasing collaborations along with drug launches
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for tularemia treatment owing to the rising research. Various collaborations, acquisitions and license agreement with technological advancements among different countries will be a crucial factor driving the growth of the market.
On February 17, 2022, researchers at Defence Science and Technology Laboratory (Dstl) have demonstrated that an antibiotic developed for the treatment of urinary tract infections is effective at treating a wide range of diseases, including plague and melioidosis. This work was done in collaboration with industry, academia, along with the Defence Threat Reduction Agency (DTRA). The antibiotic finafloxacin is being manufactured by MerLion Pharmaceuticals to treat urinary tract infections, but when compared to comparator drugs, its distinct mode of action has improved activity. In mouse infection models, finafloxacin effectively treats inhalational tularemia and plague.
Additionally, on June 25, 2021, through its American subsidiary, Hikma Pharmaceuticals USA Inc., the worldwide pharmaceutical business Hikma Pharmaceuticals PLC has introduced Doxycycline Injection, USP, 100mg, in the US. An antibiotic called doxycycline injection is used for the treatment of infections that are definitely or highly believed to be brought on by bacteria that are sensitive.
Furthermore, the rising utilization of novel medicines and solutions for tularemia treatment. Rising glandular tularemia cases and increasing utilization of several drugs along with research for innovative product development will be a major factor driving the growth of the tularemia treatment market.
Side effects associated with the drugs
One in ten persons experience these doxycycline side effects often. Headaches, feeling ill (vomiting), nausea, and sun sensitivity are examples of side effects. Serious side effects can indicate blood issues and include bleeding or bruises that cannot be explained, including nosebleeds, a sore throat, a fever, and feeling weary or generally ill.
Diarrhea that is bloody or mucus-filled, along with buzzing or ringing in the ears, and possibly stomach cramps. swallowing difficulties or pain, throat discomfort, acid reflux, a decrease in appetite, or chest pain that worsens while eating.
Segment Analysis
The global tularemia treatment market is segmented based on disease type, drugs, route of administration, distribution channel and region.
Ulceroglandular tularemia disease type segment accounted for approximately 48% of market share
By the bacteria Francisella tularensis, which is prevalent throughout the northern hemisphere, tularemia, a rare zoonotic infection, is brought on. Through inoculation from the bites of arthropod vectors like ticks or stag flies, or by handling contaminated tissue from naturally occurring animal reservoirs like rabbits or small rodents, the ulceroglandular type of illness is spread.
Other types of exposure to polluted fluid or aerosol may cause systemic "typhoidal" disease, oropharyngeal disease, oculoglandular disease, or pneumonic disease. Intravenous aminoglycosides were once the standard of care, but recent research has shown that milder cases can be successfully treated with oral antibiotics such ciprofloxacin or tetracycline. With the rising population and growing geographical reach of its tick vectors, it is possible to expect an increase in the incidence of tularemia globally.
According to Illinois Department of Public Health, every year, the United States reports between 100 and 200 instances. Tularemia can result in six different disease types, although up to 80% of cases are "ulceroglandular" (characterized by skin ulcers and enlarged lymph nodes) and are brought on by close contact involving infected animals.
Geographical Penetration
North America accounted for around 39% of market share in 2022
Due to the rising need for tularemia treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for tularemia treatment.
Increasing expenditure on healthcare, advancement of technologies and different treatment products for different tularemia disease types, along with increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of tularemia treatment market share of this region. The market in this area is growing as people become more aware of various novel treatments. The aforementioned elements attest to North America's hegemonic position in the world.
North America continues to be a key player in the global tularemia treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for antibiotics such as aminoglycosides in the United States which have been proactive in executing several initiatives or treatment, stimulating these drugs demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global tularemia treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of fluoroquinolones or tetracyclines, was significantly impacted. The widespread lockdowns and restrictions imposed by the pandemic, which began in early 2020, had an effect on a number of initiatives all around the world.
Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for tularemia treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global tularemia treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel treatments.
Key Developments
• On August 14, 2023, for Delayed-Release Doxycycline Hyclate Tablets USP, 50 mg, 60 mg, 80 mg, 100 mg, 150 mg, and 200 mg, an abbreviated novel drug application has been approved by the US Food and Drug Administration (US FDA) for marketing as a generic alternative to Doryx MPC Delayed-Release Tablets and Doryx Delayed-Release Tablets of Mayne Pharma International Pty. Ltd.
• On January 4, 2022, the US Food & Drug Administration (USFDA) has given its final approval to Alembic Pharmaceuticals Limited's Abbreviated Novel Drug Application (ANDA) for Delayed-Release, Doxycycline Hyclate Tablets USP, 100 mg, 150 mg, or 200 mg. The ANDA that has been approved is therapeutically similar to Mayne Pharma International Pty. Ltd.'s Doryx Tablets, 100 mg, 150 mg, or 200 mg.
Competitive Landscape
The major global players in the market include Pfizer Inc., Merck KGaA, Fujian Fukang Pharmaceutical Co., Ltd, Hikma Pharmaceuticals PLC, Cepham Life Sciences, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Midas Pharma GmbH, Camber Pharmaceuticals, Inc. and FUJIFILM Wako Pure Chemical Corporation.
Why Purchase the Report?
• To visualize the global tularemia treatment market segmentation based on disease type, drugs, route of administration, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of tularemia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global tularemia treatment market report would provide approximately 69 tables, 70 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drugs
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing collaborations along with drug launches
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Side effects associated with the drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Ulceroglandular Tularemia*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Glandular Tularemia
7.4. Oculoglandular Tularemia
7.5. Oropharyngeal Tularemia
7.6. Pneumonic Tularemia
7.7. Typhoidal Tularemia
8. By Drugs
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
8.1.2. Market Attractiveness Index, By Drugs
8.2. Fluoroquinolones*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Ciprofloxacin
8.2.4. Levofloxacin
8.3. Tetracyclines
8.3.1. Tetracycline
8.3.2. Doxycycline
8.4. Aminoglycosides
8.4.1. Streptomycin
8.4.2. Gentamicin
8.5. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Injection
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospitals Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Merck KGaA
13.3. Fujian Fukang Pharmaceutical Co., Ltd
13.4. Hikma Pharmaceuticals PLC
13.5. Cepham Life Sciences
13.6. Teva Pharmaceutical Industries Ltd.
13.7. Dr. Reddy’s Laboratories Ltd.
13.8. Midas Pharma GmbH
13.9. Camber Pharmaceuticals, Inc.
13.10. FUJIFILM Wako Pure Chemical Corporation
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4. Key Developments, Merck KGaA, Fujian Fukang Pharmaceutical Co., Ltd, Hikma Pharmaceuticals PLC, Cepham Life Sciences, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Midas Pharma GmbH, Camber Pharmaceuticals, Inc., FUJIFILM Wako Pure Chemical Corporation

표 목록 (Tables)

List of Tables

Table 1 Global Tularemia Treatment Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Tularemia Treatment Market Value, By Drugs, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Tularemia Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Tularemia Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Tularemia Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Tularemia Treatment Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Tularemia Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 8 Global Tularemia Treatment Market Value, By Drugs, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Tularemia Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 10 Global Tularemia Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Tularemia Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 12 Global Tularemia Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Tularemia Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 14 Global Tularemia Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Tularemia Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Tularemia Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 17 North America Tularemia Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 18 North America Tularemia Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 North America Tularemia Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 North America Tularemia Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Tularemia Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 22 South America Tularemia Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 23 South America Tularemia Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 24 South America Tularemia Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 25 South America Tularemia Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Tularemia Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 27 Europe Tularemia Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 28 Europe Tularemia Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 29 Europe Tularemia Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 Europe Tularemia Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Tularemia Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Tularemia Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Tularemia Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Tularemia Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Tularemia Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Tularemia Treatment Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Tularemia Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Tularemia Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Tularemia Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 40 Pfizer Inc.: Overview

Table 41 Pfizer Inc.: Product Portfolio

Table 42 Pfizer Inc.: Key Developments

Table 43 Merck KGaA: Overview

Table 44 Merck KGaA: Product Portfolio

Table 45 Merck KGaA: Key Developments

Table 46 Fujian Fukang Pharmaceutical Co., Ltd: Overview

Table 47 Fujian Fukang Pharmaceutical Co., Ltd: Product Portfolio

Table 48 Fujian Fukang Pharmaceutical Co., Ltd: Key Developments

Table 49 Hikma Pharmaceuticals PLC: Overview

Table 50 Hikma Pharmaceuticals PLC: Product Portfolio

Table 51 Hikma Pharmaceuticals PLC: Key Developments

Table 52 Cepham Life Sciences: Overview

Table 53 Cepham Life Sciences: Product Portfolio

Table 54 Cepham Life Sciences: Key Developments

Table 55 Teva Pharmaceutical Industries Ltd.: Overview

Table 56 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 57 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 58 Dr. Reddy’s Laboratories Ltd.: Overview

Table 59 Dr. Reddy’s Laboratories Ltd.: Product Portfolio

Table 60 Dr. Reddy’s Laboratories Ltd.: Key Developments

Table 61 Midas Pharma GmbH: Overview

Table 62 Midas Pharma GmbH: Product Portfolio

Table 63 Midas Pharma GmbH: Key Developments

Table 64 Camber Pharmaceuticals, Inc.: Overview

Table 65 Camber Pharmaceuticals, Inc.: Product Portfolio

Table 66 Camber Pharmaceuticals, Inc.: Key Developments

Table 67 FUJIFILM Wako Pure Chemical Corporation: Overview

Table 68 FUJIFILM Wako Pure Chemical Corporation: Product Portfolio

Table 69 FUJIFILM Wako Pure Chemical Corporation: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Tularemia Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 3 Global Tularemia Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 4 Global Tularemia Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Tularemia Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Tularemia Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Tularemia Treatment Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 8 Ulceroglandular Tularemia Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Glandular Tularemia Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Oculoglandular Tularemia Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Oropharyngeal Tularemia Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Pneumonic Tularemia Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Typhoidal Tularemia Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Global Tularemia Treatment Market Y-o-Y Growth, By Drugs, 2022-2030 (%)

Figure 15 Fluoroquinolones Drugs in Global Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Tetracyclines Drugs in Global Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Aminoglycosides Drugs in Global Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Others Drugs Dermatitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Global Tularemia Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 20 Oral Route of Administration in Global Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 Injection Route of Administration in Global Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Global Tularemia Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 23 Hospitals Pharmacies Distribution Channel in Global Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 Retail Pharmacies Distribution Channel in Global Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Online Pharmacies Distribution Channel in Global Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 Global Tularemia Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 27 North America Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 28 Asia-Pacific Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 Europe Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 30 South America Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 31 Middle East and Africa Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 32 North America Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 33 North America Tularemia Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 34 North America Tularemia Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 35 North America Tularemia Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 36 North America Tularemia Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 37 North America Tularemia Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 38 South America Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 39 South America Tularemia Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 40 South America Tularemia Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 41 South America Tularemia Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 42 South America Tularemia Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 43 South America Tularemia Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 44 Europe Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 45 Europe Tularemia Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 46 Europe Tularemia Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 47 Europe Tularemia Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 48 Europe Tularemia Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 49 Europe Tularemia Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 50 Asia-Pacific Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 51 Asia-Pacific Tularemia Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 52 Asia-Pacific Tularemia Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 53 Asia-Pacific Tularemia Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 54 Asia-Pacific Tularemia Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 55 Asia-Pacific Tularemia Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 56 Middle East & Africa Tularemia Treatment Market Value, 2021-2030 (US$ Million)

Figure 57 Middle East & Africa Tularemia Treatment Market Share, By Disease Type, 2022 & 2030 (%)

Figure 58 Middle East & Africa Tularemia Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 59 Middle East & Africa Contact Dermatitis Route of Administration Market Share, By Treatment, 2022 & 2030 (%)

Figure 60 Middle East & Africa Tularemia Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 61 Pfizer Inc.: Financials

Figure 62 Merck KGaA: Financials

Figure 63 Fujian Fukang Pharmaceutical Co., Ltd: Financials

Figure 64 Hikma Pharmaceuticals PLC: Financials

Figure 65 Cepham Life Sciences: Financials

Figure 66 Teva Pharmaceutical Industries Ltd.: Financials

Figure 67 Dr. Reddy’s Laboratories Ltd.: Financials

Figure 68 Midas Pharma GmbH: Financials

Figure 69 Camber Pharmaceuticals, Inc.: Financials

Figure 70 FUJIFILM Wako Pure Chemical Corporation: Financials

세계 툴라레미아 치료 시장 – 2023-2030

Global Tularemia Treatment Market -2023-2030